Overview
- 6 inspections across 6 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-03-27.
At a glance
Inspections
6
Sites
6
Observations
0
Career since
Mar 2024
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Q-Med AB | 27 Mar 2026 | Human Drugs | On file |
| GlaxoSmithKline Manufacturing S.p.A. | 15 May 2025 | Human Drugs | On file |
| GlaxoSmithKline LLC | 7 Mar 2025 | Human Drugs | On file |
| KBI Biopharma, Inc. | 18 Jun 2024 | Human Drugs | On file |
| KBI Biopharma, Inc. | 17 Jun 2024 | Human Drugs |
Sites inspected
Q-Med ABUppsala, Sweden1 insp.
GlaxoSmithKline Manufacturing S.p.A.Torrile, Italy1 insp.
GlaxoSmithKline LLCConshohocken, United States1 insp.
KBI Biopharma, Inc.Durham, United States1 insp.
KBI Biopharma, Inc.Durham, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Madushini N Dharmasena2 shared
Kamal N Tiwari2 shared
Ayyappan Rathakrishnan2 shared
Michael Shanks2 shared
Qibing Zhou1 shared
Jun Liu1 shared
Shadia Zaman1 shared
Hamet M Toure1 shared
Sarah A Johnson1 shared
Karina M Zuck1 shared
Full investigator report
Get the verbatim findings behind Olumide A Martins' inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site